天士力：产品“注射用重组人尿激酶原”取得注册证

Core Viewpoint - Tianjin Tasly Pharmaceutical Group Co., Ltd. has received approval from the National Medical Products Administration for a new indication of its innovative biological drug, recombinant human urokinase (Puyouke), for thrombolytic treatment of acute ischemic stroke [1] Company Summary - Tasly's subsidiary, Tasly Biopharmaceuticals, has been granted a drug registration certificate for the new indication, marking the second approved indication for Puyouke in China [1] - The drug was developed under the "Major New Drug Creation" program during the 11th Five-Year Plan and is classified as a Class 1 innovative biological drug [1] - As of the latest report, Tasly's market capitalization stands at 23.5 billion yuan [1] Revenue Composition - For the year 2024, Tasly's revenue composition is as follows: Traditional Chinese medicine accounts for 70.89%, chemical drugs for 15.38%, pharmaceutical commerce for 10.53%, biological drugs for 2.25%, and chemical raw materials for 0.61% [1]